Vandetanib for thyroid cancer

被引：0
|
作者：
Takahashi, Shunji [1 ]
机构：
[1] JFCR, Canc Inst Hosp, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ISY-6-1
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer
    Hu, Mimi I.
    Elisei, Rossella
    Dedecjus, Marek
    Popovtzer, Aron
    Druce, Maralyn
    Kapiteijn, Ellen
    Pacini, Furio
    Locati, Laura
    Krajewska, Jolanta
    Weiss, Richard
    Gagel, Robert F.
    ENDOCRINE-RELATED CANCER, 2019, 26 (02) : 241 - 250
  • [42] Phototoxic drug eruption induced by vandetanib used for the treatment of metastatic medullary thyroid cancer
    Bostan, Ecem
    Gulseren, Duygu
    Gokoz, Ozay
    ANAIS BRASILEIROS DE DERMATOLOGIA, 2022, 97 (05) : 695 - 696
  • [43] Vandetanib: A novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer
    Ton, GiangThy N.
    Banaszynski, Megan E.
    Kolesar, Jill M.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (10) : 849 - 855
  • [44] Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer
    Koehler, Viktoria F.
    Adam, Pia
    Frank-Raue, Karin
    Raue, Friedhelm
    Berg, Elke
    Hoster, Eva
    Allelein, Stephanie
    Schott, Matthias
    Kroiss, Matthias
    Spitzweg, Christine
    THYROID, 2021, 31 (03) : 459 - 469
  • [45] Meta-Analysis of the Efficacy and Safety Evaluation of Vandetanib in the Treatment of Medullary Thyroid Cancer
    Xian, Tong-cheng
    Yang, Min-ye
    Zhang, Xue-lin
    Wang, Jie
    Luo, Yi
    HORMONE AND METABOLIC RESEARCH, 2024, 56 (09) : 649 - 653
  • [46] Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience
    Kim, Mijin
    Yoon, Jee Hee
    Ahn, Jonghwa
    Jeon, Min Ji
    Kim, Hee Kyung
    Lim, Dong Jun
    Kang, Ho-Cheol
    Kim, In Joo
    Shong, Young Kee
    Kim, Tae Yong
    Kim, Bo Hyun
    ENDOCRINOLOGY AND METABOLISM, 2020, 35 (03) : 587 - 594
  • [47] Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
    Robinson, Bruce G.
    Paz-Ares, Luis
    Krebs, Annetta
    Vasselli, James
    Haddad, Robert
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (06): : 2664 - 2671
  • [48] Efficacy and Toxicity of Vandetanib for Advanced Medullary Thyroid Cancer Treatment in Real Life Conditions
    Chougnet, Cecile N.
    Borget, Isabelle
    Tuthyref, Network
    Schlumberger, Martin Jean
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [49] AN INDIRECT TREATMENT COMPARISON OF CABOZANTINIB VERSE VANDETANIB IN PROGRESSIVE MEDULLARY THYROID CANCER (MTC)
    Rinciog, C.
    Myren, K. J.
    Alden, M.
    Diamantopoulos, A.
    LeReun, C.
    VALUE IN HEALTH, 2014, 17 (07) : A616 - A616
  • [50] Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment
    Werner, R. A.
    Schmid, J. S.
    Muegge, D. O.
    Lueckerath, K.
    Higuchi, T.
    Haenscheid, H.
    Grelle, I.
    Reiners, C.
    Herrmann, K.
    Buck, A. K.
    Lapa, C.
    MEDICINE, 2015, 94 (45) : e2016
12345